Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE versus THEOLAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE versus THEOLAIR.
AEROLATE vs THEOLAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline competitively inhibits phosphodiesterase, increasing cAMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular cAMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/mL. Maintenance: 400-600 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Adults: 3-8 hours (mean 5.5); children: 1.5-5 hours; increased in hepatic cirrhosis, heart failure, and COPD; decreased in smokers
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Renal (10% unchanged); hepatic metabolism (90%) with metabolites excreted in urine
Category C
Category C
Bronchodilator
Bronchodilator